Compare Stocks: IMNM, HALO, ARWR, and KRYS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$82.89 +0.2%	$84.32	$28.12 ▼ $95.49	$11.68B	1.28	2.27 million shs	1.34 million shs
HALO Halozyme Therapeutics	$107.20 +0.2%	$93.18	$61.22 ▼ $111.15	$12.17B	0.88	1.84 million shs	861,275 shs
IMNM Immunome	$24.67 -1.2%	$25.31	$8.93 ▼ $30.06	$2.80B	2.13	1.34 million shs	692,557 shs
KRYS Krystal Biotech	$347.00 +0.4%	$347.95	$141.24 ▼ $382.54	$10.27B	0.54	332,818 shs	206,248 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+0.16%	-4.31%	-7.26%	+11.06%	+186.47%
HALO Halozyme Therapeutics	-0.36%	-3.39%	+4.27%	+53.96%	+41.16%
IMNM Immunome	-4.40%	-8.06%	-4.88%	+35.85%	+177.44%
KRYS Krystal Biotech	-0.73%	-6.98%	+5.66%	+8.67%	+151.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$82.89 +0.2%	$84.32	$28.12 ▼ $95.49	$11.68B	1.28	2.27 million shs	1.34 million shs
HALO Halozyme Therapeutics	$107.20 +0.2%	$93.18	$61.22 ▼ $111.15	$12.17B	0.88	1.84 million shs	861,275 shs
IMNM Immunome	$24.67 -1.2%	$25.31	$8.93 ▼ $30.06	$2.80B	2.13	1.34 million shs	692,557 shs
KRYS Krystal Biotech	$347.00 +0.4%	$347.95	$141.24 ▼ $382.54	$10.27B	0.54	332,818 shs	206,248 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+0.16%	-4.31%	-7.26%	+11.06%	+186.47%
HALO Halozyme Therapeutics	-0.36%	-3.39%	+4.27%	+53.96%	+41.16%
IMNM Immunome	-4.40%	-8.06%	-4.88%	+35.85%	+177.44%
KRYS Krystal Biotech	-0.73%	-6.98%	+5.66%	+8.67%	+151.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.64	Moderate Buy	$99.15	19.66% Upside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-15.04% Downside
IMNM Immunome	2.85	Moderate Buy	$34.64	39.16% Upside
KRYS Krystal Biotech	2.92	Moderate Buy	$365.40	4.71% Upside

Current Analyst Ratings Breakdown

Latest IMNM, HALO, ARWR, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	IMNM Immunome	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/8/2026	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$108.00
9/2/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
9/1/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
8/31/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/31/2026	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$100.00
8/31/2026	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
8/18/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/17/2026	ARWR Arrowhead Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/14/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	14.07	$0.12 per share	692.04	$3.64 per share	22.76
HALO Halozyme Therapeutics	$1.40B	8.72	$4.77 per share	22.51	$0.42 per share	255.60
IMNM Immunome	$6.94M	407.35	N/A	N/A	$5.75 per share	4.33
KRYS Krystal Biotech	$440.48M	23.45	$7.31 per share	47.75	$42.06 per share	8.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	11/24/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	32.06	11.59	0.42	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	43.86	37.40	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)

Latest IMNM, HALO, ARWR, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
HALO Halozyme Therapeutics	13.50	2.71	2.31
IMNM Immunome	N/A	15.08	15.08
KRYS Krystal Biotech	N/A	8.32	7.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
HALO Halozyme Therapeutics	97.79%
IMNM Immunome	44.58%
KRYS Krystal Biotech	86.29%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
HALO Halozyme Therapeutics	2.50%
IMNM Immunome	7.21%
KRYS Krystal Biotech	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	711	140.86 million	135.79 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable
IMNM Immunome	40	113.58 million	105.39 million	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable

IMNM, HALO, ARWR, and KRYS Headlines

Recent News About These Companies

Krystal Biotech, Inc. $KRYS Shares Purchased by California State Teachers Retirement System

September 11 at 3:59 AM | marketbeat.com

Hsbc Holdings PLC Invests $3.65 Million in Krystal Biotech, Inc. $KRYS

September 11 at 3:36 AM | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Holdings in Krystal Biotech, Inc. $KRYS

September 10 at 5:27 AM | marketbeat.com

C WorldWide Group Holding A S Trims Stake in Krystal Biotech, Inc. $KRYS

September 9 at 7:11 AM | marketbeat.com

Wellington Management Group LLP Acquires 26,709 Shares of Krystal Biotech, Inc. $KRYS

September 8 at 5:03 AM | marketbeat.com

Suma Krishnan Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

September 5, 2026 | insidertrades.com

Krystal Biotech, Inc. $KRYS is Odyssean LLC's 10th Largest Position

September 5, 2026 | marketbeat.com

Insider Selling: Krystal Biotech (NASDAQ:KRYS) Insider Sells $8,983,000.00 in Stock

September 4, 2026 | marketbeat.com

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

September 3, 2026 | zacks.com

Krystal Biotech to Participate in 2026 Cantor Global Healthcare Conference

September 3, 2026 | quiverquant.comQ

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

September 3, 2026 | globenewswire.com

Van ECK Associates Corp Invests $6.34 Million in Krystal Biotech, Inc. $KRYS

September 3, 2026 | marketbeat.com

Krystal Biotech, Inc. $KRYS Stock Holdings Decreased by Braidwell LP

September 3, 2026 | marketbeat.com

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

September 2, 2026 | zacks.com

Hsbc Holdings PLC Purchases Shares of 9,598 Krystal Biotech, Inc. $KRYS

August 30, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Makes New Investment in Krystal Biotech, Inc. $KRYS

August 30, 2026 | marketbeat.com

Legal & General Group Plc Makes New Investment in Krystal Biotech, Inc. $KRYS

August 30, 2026 | marketbeat.com

Corient Private Wealth LP Makes New Investment in Krystal Biotech, Inc. $KRYS

August 30, 2026 | marketbeat.com

Toth Financial Advisory Corp Acquires 4,505 Shares of Krystal Biotech, Inc. $KRYS

August 29, 2026 | marketbeat.com

256,665 Shares in Krystal Biotech, Inc. $KRYS Bought by Jupiter Topco LLC

August 27, 2026 | marketbeat.com

OMERS ADMINISTRATION Corp Takes $1.44 Million Position in Krystal Biotech, Inc. $KRYS

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMNM, HALO, ARWR, and KRYS Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$82.89 +0.13 (+0.16%)

Closing price 04:00 PM Eastern

Extended Trading

$82.50 -0.39 (-0.47%)

As of 04:59 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Halozyme Therapeutics NASDAQ:HALO

$107.20 +0.20 (+0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$106.32 -0.88 (-0.82%)

As of 05:31 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Immunome NASDAQ:IMNM

$24.67 -0.30 (-1.20%)

Closing price 04:00 PM Eastern

Extended Trading

$24.68 +0.01 (+0.04%)

As of 04:32 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Krystal Biotech NASDAQ:KRYS

$347.00 +1.45 (+0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$348.83 +1.83 (+0.53%)

As of 05:23 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMNM, HALO, ARWR, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMNM, HALO, ARWR, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMNM, HALO, ARWR, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMNM, HALO, ARWR, and KRYS Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Halozyme Therapeutics NASDAQ:HALO

Immunome NASDAQ:IMNM

Krystal Biotech NASDAQ:KRYS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMNM, HALO, ARWR, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMNM, HALO, ARWR, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMNM, HALO, ARWR, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMNM, HALO, ARWR, and KRYS Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Halozyme Therapeutics NASDAQ:HALO

Immunome NASDAQ:IMNM

Krystal Biotech NASDAQ:KRYS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools